BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $212,000 | -20.0% | 609 | -0.2% | 0.00% | 0.0% |
| Q1 2022 | $265,000 | -8.9% | 610 | +8.9% | 0.00% | 0.0% |
| Q4 2021 | $291,000 | +10.2% | 560 | +2.9% | 0.00% | +33.3% |
| Q3 2021 | $264,000 | -10.2% | 544 | -16.4% | 0.00% | 0.0% |
| Q2 2021 | $294,000 | -80.3% | 651 | -83.3% | 0.00% | -82.4% |
| Q1 2021 | $1,491,000 | +8.6% | 3,897 | -9.7% | 0.02% | +6.2% |
| Q4 2020 | $1,373,000 | +175.2% | 4,317 | +114.7% | 0.02% | +166.7% |
| Q3 2020 | $499,000 | +4.0% | 2,011 | +11.0% | 0.01% | 0.0% |
| Q2 2020 | $480,000 | +22.8% | 1,811 | -12.0% | 0.01% | +20.0% |
| Q1 2020 | $391,000 | +24.1% | 2,058 | +28.0% | 0.01% | +66.7% |
| Q3 2019 | $315,000 | -6.2% | 1,608 | 0.0% | 0.00% | -25.0% |
| Q2 2019 | $336,000 | +5.0% | 1,608 | 0.0% | 0.00% | +33.3% |
| Q1 2019 | $320,000 | +37.3% | 1,608 | -0.1% | 0.00% | 0.0% |
| Q4 2018 | $233,000 | -29.2% | 1,609 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $329,000 | -66.9% | 1,609 | -76.0% | 0.00% | -66.7% |
| Q2 2018 | $993,000 | -2.1% | 6,710 | -0.0% | 0.01% | -7.7% |
| Q1 2018 | $1,014,000 | +365.1% | 6,712 | +178.3% | 0.01% | +160.0% |
| Q4 2015 | $218,000 | -80.1% | 2,412 | -79.7% | 0.01% | -81.5% |
| Q3 2015 | $1,098,000 | -81.8% | 11,863 | -80.7% | 0.03% | -80.9% |
| Q2 2015 | $6,048,000 | +0.5% | 61,418 | +2.3% | 0.14% | -2.1% |
| Q1 2015 | $6,020,000 | +37.7% | 60,020 | +26.8% | 0.14% | +19.0% |
| Q4 2014 | $4,373,000 | +23.7% | 47,320 | +25.3% | 0.12% | +10.0% |
| Q3 2014 | $3,534,000 | – | 37,768 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |